Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash.
CAMBRIDGE, Mass., May 20, 2024 Foghorn Therapeutics Inc. today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share,.
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation.